(IBTH) iShares iBonds Dec 2027 - Ratings and Ratios
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • ISIN: US46436E8416 • Target Maturity
IBTH: U.S. Treasury Securities, Bonds, Government Debt
The iShares iBonds Dec 2027 Term Treasury ETF (NASDAQ: IBTH) is designed to provide exposure to U.S. Treasury securities with maturities focused around December 2027. The fund is structured as a target maturity ETF, meaning it will hold securities until they mature, at which point it will liquidate. This approach allows investors to gain exposure to a specific segment of the Treasury yield curve, which can be particularly useful for those seeking to manage interest rate risk or ladder their bond exposure.
The underlying index for IBTH consists of publicly-issued U.S. Treasury securities scheduled to mature between January 1, 2027, and December 15, 2027. This narrow maturity range makes the ETF appealing for investors who want precise exposure to Treasuries maturing around that specific time frame. The fund will invest at least 80% of its assets in the component securities of the underlying index and at least 90% in U.S. Treasury securities overall. This ensures that the ETF remains tightly aligned with its target maturity objective while maintaining strict adherence to its investment mandate.
As of the latest data, the ETF has an assets under management (AUM) of $1.369 billion, indicating a sizable and liquid fund. The ETF is managed by BlackRock Fund Advisors (BFA), which brings significant expertise in fixed-income investing and index tracking. Given its focus on U.S. Treasuries, the fund does not report traditional equity metrics like P/E, P/B, or P/S, as these are not relevant for fixed-income securities. Instead, investors should focus on yield, duration, and credit quality when evaluating this ETF.
IBTH is listed on the NASDAQ exchange under the ticker symbol IBTH, and it is categorized as a U.S.-originated ETF in the target maturity segment. This structure makes it a straightforward tool for investors and fund managers looking to add targeted Treasury exposure to their portfolios. The ETFs transparency and predictable maturity date can be particularly valuable for constructing laddered portfolios or for investors seeking to match liabilities with a specific duration.
Additional Sources for IBTH ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
IBTH ETF Overview
Market Cap in USD | 1,441m |
Category | Target Maturity |
TER | 0.07% |
IPO / Inception | 2020-02-25 |
IBTH ETF Ratings
Growth 5y | -3.41% |
Fundamental | - |
Dividend | 73.2% |
Rel. Strength Industry | -1.73 |
Analysts | - |
Fair Price Momentum | 21.62 USD |
Fair Price DCF | - |
IBTH Dividends
Dividend Yield 12m | 3.71% |
Yield on Cost 5y | 3.62% |
Annual Growth 5y | 46.70% |
Payout Consistency | 100.0% |
IBTH Growth Ratios
Growth Correlation 3m | 90.8% |
Growth Correlation 12m | 85% |
Growth Correlation 5y | -62.4% |
CAGR 5y | -0.31% |
CAGR/Max DD 5y | -0.02 |
Sharpe Ratio 12m | 0.58 |
Alpha | 0.88 |
Beta | 0.02 |
Volatility | 1.76% |
Current Volume | 171.9k |
Average Volume 20d | 352.5k |
As of March 14, 2025, the stock is trading at USD 22.37 with a total of 171,900 shares traded.
Over the past week, the price has changed by +0.13%, over one month by +1.14%, over three months by +1.65% and over the past year by +5.16%.
Neither. Based on ValueRay Analyses, iShares iBonds Dec 2027 is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -3.41 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IBTH as of March 2025 is 21.62. This means that IBTH is currently overvalued and has a potential downside of -3.35%.
iShares iBonds Dec 2027 has no consensus analysts rating.
According to ValueRays Forecast Model, IBTH iShares iBonds Dec 2027 will be worth about 23.4 in March 2026. The stock is currently trading at 22.37. This means that the stock has a potential upside of +4.38%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 23.4 | 4.4% |